COMMUNIQUÉS West-GlobeNewswire

Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to January 31, 2025

26/09/2024 - 15:00

US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up period on the Scilex Dividend Stock, previously distributed by Sorrento, to January 31, 2025. Accordingly, any shares of the [...]

Hapbee Appoints Mr. Abdulla Al Zain to Board of Directors

26/09/2024 - 15:00

Appointment indicates Hapbee’s commitment to expand in the Middle East and globally MONTRÉAL, Sept. 26, 2024 (GLOBE NEWSWIRE) -- CNW Telbec/ - Hapbee Technologies, Inc. (TSXV: HAPB ) (OTCQB: HAPBF) (FSE: HA1) ("Hapbee" [...]

Units for Debt Settlement

26/09/2024 - 14:46

TORONTO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company has arranged a transaction to settle an aggregate total [...]

OneMedNet Announces Additional $1.7 Million Private Placement

26/09/2024 - 14:45

MINNEAPOLIS, Sept. 26, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading curator of regulatory-grade Real World Data ("RWD"), inclusive of electronic health [...]

International Myeloma Foundation to Hold First Latin American Myeloma Network Summit in Brazil on September 28

26/09/2024 - 14:45

The inaugural IMF Latin American Myeloma Network Summit will take place on Saturday, September 28, after the International Myeloma Society (IMS) Meeting in Rio De Janeiro, Brazil RIO DE JANEIRO, Brazil, Sept. 26, 2024 ( [...]

Fortress Biotech to Participate in October 2024 Investor Conferences

26/09/2024 - 14:30

MIAMI, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders [...]

Interim results for the six months ended June 30, 2024

26/09/2024 - 14:30

September 26, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Interim results for the six months ended June 30, 2024 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an acquisition-focused clinical stage [...]

Montreal hosts the 4th International Symposium on Arthrogryposis Multiplex Congenita (AMC)

26/09/2024 - 14:30

MONTREAL, Sept. 26, 2024 (GLOBE NEWSWIRE) -- From September 28 to October 1, the Shriners Hospitals for Children - Canada will host the 4 th International Symposium on Arthrogryposis . Organized in collaboration with [...]

Impact BioMedical Inc. (NYSE: IBO) Announces 3F™ US Patent Issue

26/09/2024 - 14:30

HOUSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (“IBO”) is pleased to announce that the US Patent and Trademark Office has issued U.S. Patent No. 11,985,973 entitled “Insect Repelling Composition” [...]

Montréal accueille le 4e Symposium international sur l’arthrogrypose congénitale multiple (ACM)

26/09/2024 - 14:30

MONTREAL, 26 sept. 2024 (GLOBE NEWSWIRE) -- Du 28 septembre au 1er octobre prochains, l’Hôpital Shriners pour enfants Canada sera l’hôte du 4ème symposium international sur l'arthrogrypose . Organisé en collaboration [...]

Gynesonics Announces New SMART OS™ Software Technology for Sonata® System Treatment of Uterine Fibroids

26/09/2024 - 14:30

Revolutionizing Fibroid Treatment with Enhanced Precision, Control & Flexibility REDWOOD CITY, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Gynesonics Inc., a medical device company focused on the development of [...]

Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference

26/09/2024 - 14:30

CUPERTINO, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet [...]

Kane Biotech Announces Attendance at Upcoming Wound Care Conferences

26/09/2024 - 14:30

WINNIPEG, Manitoba, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that the Company will be showcasing its revyve™ Antimicrobial Wound [...]

Allogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases, at the American College of Rheumatology (ACR) Convergence

26/09/2024 - 14:30

The CD19/CD70 Dual CAR is Specifically Designed to Address Both the B-cell and T-cell Dysfunction Implicated in Autoimmune Diseases ALLO-329, is an Investigational Product Built on a New Gene Editing Platform that [...]

Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

26/09/2024 - 14:30

Nes-Ziona, Israel, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Danish Medicines [...]

Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts

26/09/2024 - 14:05

GAITHERSBURG, Md., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent”) today announced that two contract options have been secured to procure additional treatment courses of TEMBEXA [...]

Nuvo Group Retains Intrepid Investment Bankers to Explore Investment and Strategic Alternatives

26/09/2024 - 14:00

TEL AVIV, Israel, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Holdco Nuvo Group D.G Ltd (“Nuvo”), a pioneer in remote pregnancy monitoring, filed a motion on September 10, 2024 to retain Intrepid Investment Bankers (“Intrepid”) [...]

Repair Biotechnologies and Genevant Sciences to Collaborate to Develop mRNA-LNP Therapy with First-in-Class Potential to Turn Back Atherosclerosis

26/09/2024 - 14:00

SYRACUSE, New York, VANCOUVER, British Columbia, and BASEL, Switzerland, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Repair Biotechnologies, a biotechnology company developing first-in-class therapies capable of rapidly [...]

Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting

26/09/2024 - 14:00

NOVATO, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it will present seven abstracts related to its ongoing late-stage program evaluating setrusumab ( [...]